Intarcia Therapeutics Revenue and Competitors

Boston, MA USA

Location

$1.7B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Intarcia Therapeutics's estimated annual revenue is currently $16.3M per year.(i)
  • Intarcia Therapeutics received $206.0M in venture funding in December 2016.
  • Intarcia Therapeutics's estimated revenue per employee is $155,000
  • Intarcia Therapeutics's total funding is $1.7B.
  • Intarcia Therapeutics's current valuation is $3.8B.

Employee Data

  • Intarcia Therapeutics has 105 Employees.(i)
  • Intarcia Therapeutics grew their employee count by 7% last year.

Intarcia Therapeutics's People

NameTitleEmail/Phone
1
VP, Regulatory Affairs CMCReveal Email/Phone
2
VP, Development, Technology, & EngineeringReveal Email/Phone
3
VP, Head Statistics, Programming, and Data ManagementReveal Email/Phone
4
CXO - Chief Experience Officer - Head Customer Experience & OutcomesReveal Email/Phone
5
Director Business OperationsReveal Email/Phone
6
Assoc. Director, Lean Six SigmaReveal Email/Phone
7
Executive Director, Corporate ControllerReveal Email/Phone
8
Chief Legal OfficerReveal Email/Phone
9
Director, MSAT Corporate ValidationReveal Email/Phone
10
Sr Manager, Asset Lifecycle ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Intarcia Therapeutics?

At Intarcia Therapeutics, Inc., employees are the keys to our purpose and success. We unleash our team's talent, to unlock life's possibilities for patients with disruptively innovative medicines. Intarcia is a rapidly growing biopharmaceutical company developing innovative therapies that merge medicine and technology. We seek to transform the standard of care and improve patient outcomes in major therapeutic categories for serious chronic diseases, such as diabetes. We successfully completed our Phase 3 clinical trial program and submitted our New Drug Application filing for ITCA 650 in the U.S. in 2016. We are also developing a pipeline of products for our proprietary Medici Drug Delivery System™ comprised of three unique technologies: 1) A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more; 2) A matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication; and 3) A placement technology including proprietary tools designed to provide an optimal user experience Intarcia LinkedIn Community Guidelines Welcome and thank you for engaging with us. We kindly ask you to follow our community guidelines below. • We are in a regulated industry and may not be able to respond to all posts. • While we support an open forum, please be respectful. • Please avoid mentions of brand name products. • We will not provide medical advice; for questions, please consult with your healthcare provider. • We do not endorse and are not responsible for third party links/content. • Please respect all trademark and copyright rules. • By interacting here, you agree to comply with LinkedIn's rules and policies. • Failure to follow our guidelines may result in deletion of comments.

keywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals

$1.7B

Total Funding

105

Number of Employees

$16.3M

Revenue (est)

7%

Employee Growth %

$3.8B

Valuation

N/A

Accelerator

Intarcia Therapeutics News

2022-04-19 - Human Use Implantable Pump Market Forecast 2022-2030 ...

Abbott; Intarcia Therapeutics; Flowonix Medical; Cognos Therapeutics. Human Use Implantable Pump Market Breakdown by Type: 20 mL Grade Reservoir Volume...

2022-04-17 - Global GLP-1 Receptor Agonist Market Research Report to ...

Intarcia Therapeutics, Inc. 15.9. Jiangsu Hengrui Medicine Co., Ltd 15.10. Novo Nordisk A/S 15.11. Optum, Inc. 15.12. PegBio Co., Ltd.

2019-09-12 - Non-Insulin Therapies for Diabetes Market to Witness Huge Growth by 2025 | Hospital Pharmacy, Retail Pharmacies, Online Pharmacy, Others

Comprehensive company profiles of key market players within the industry, including GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, ...

2019-08-24 - Gallstones may occur with liraglutide treatment

... received travel support from Berlin-Chemie, Eli Lilly, Intarcia Therapeutics/Servier, Merck Sharp & Dohme and Novo Nordisk; and received ...

2019-08-24 - Global Non-insulin Diabetes Therapeutics Market 2019 GSK ...

The top Players/Vendors GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Jiangsu Hansoh Pharmaceutical, Novo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.8M1057%$28.4M
#2
$15.2M105-1%N/A
#3
$13.7M105-14%$22.9M
#4
$15.2M1053%N/A
#5
$22.1M1056%N/A

Intarcia Therapeutics Funding

DateAmountRoundLead InvestorsReference
2004-12-02$50.0MEMultipleArticle
2007-03-20$50.0MBBNew Leaf Venture PartnersArticle
2010-09-09$5.0MUndisclosedNew Leaf Venture Partners, Venrock AssociatesArticle
2012-11-16$210.0MUndisclosedMorgan StanleyArticle
2014-04-02$200.0MUndisclosedRA CapitalArticle
2015-04-29$225.0MUndisclosedMorgan Stanley & Co. LLCArticle
2015-06-03$75.0MUndisclosedMorgan Stanley & Co. LLCArticle
2016-05-09$75.0MUndisclosedArticle
2016-09-16$215.0MUndisclosedArticle
2016-12-30$206.0MUndisclosedMorgan Stanley & Co. LLCArticle